Browse studies

Find your next paid study

13 recruiting studies matching your filters

A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed…

Solid Tumor, AdultMicrosatellite Stable Colorectal CancerHead and Neck Squamous Cell Carcinoma+10 more

Estimated

~$10 – $8,750

KaliVir ImmunotherapeuticsNCT06444815